Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2017 Summary According to the recently published report 'C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2017'; C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 26 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells. The report 'C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2017' outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 8 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Cardiovascular, Immunology, Respiratory, Gastrointestinal, Genetic Disorders, Hematological Disorders, Ophthalmology and Women's Health which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Human Immunodeficiency Virus (HIV) Infections (AIDS), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Uveal Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Asthma, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Liver Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myocardial Infarction, Neuroblastoma, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Ductal Adenocarcinoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia, Vasomotor Symptoms of Menopause (Hot Flashes), Waldenstrom Macroglobulinemia, Wet (Neovascular / Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis). Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects - The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents
2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Overview 9 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Development 10 Products under Development by Stage of Development 10 Products under Development by Therapy Area 11 Products under Development by Indication 12 Products under Development by Companies 16 Products under Development by Universities/Institutes 21 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Therapeutics Assessment 23 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Companies Involved in Therapeutics Development 28 AdAlta Ltd 28 Ambrx Inc 29 BioLineRx Ltd 29 Bristol-Myers Squibb Company 30 Eli Lilly and Company 31 Globavir Biosciences Inc 31 GlycoMimetics Inc 32 Pfizer Inc 33 Pharis Biotec GmbH 33 Polyphor Ltd 34 TaiGen Biotechnology Co Ltd 34 Upsher-Smith Laboratories Inc 35 X4 Pharmaceuticals Inc 35 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Drug Profiles 36 AD-114 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 ALB-408 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 AM-3114 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 balixafortide - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 BL-8040 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 burixafor - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 GBV-4086 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 GMI-1359 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 HPH-112 - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 HPH-196 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 HPH-211 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 hz-515H7 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 LY-2510924 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 PF-06747143 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 POL-5551 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Protein to Agonize CXCR4 for Inflammation - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 PTX-9908 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Q-122 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 Recombinant Protein to Antagonize CXCR4 for Oncology - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 ulocuplumab - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 USL-311 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 X-4P001 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 X-4P002 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Dormant Products 83 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Discontinued Products 87 C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Product Development Milestones 88 Featured News & Press Releases 88 Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update 88 Jul 10, 2017: BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration 89 Jun 01, 2017: BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors 90 May 25, 2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 90 May 22, 2017: BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML 91 May 08, 2017: AdAlta to present eye fibrosis data at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 91 May 03, 2017: BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA 92 Mar 21, 2017: AdAlta expands collaboration with The Alfred Hospital 92 Mar 20, 2017: BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment 93 Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017 94 Jan 30, 2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease 95 Jan 26, 2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell 95 Jan 18, 2017: AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease 96 Jan 17, 2017: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer 96 Jan 09, 2017: AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential 97 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 99 Disclaimer 100
List of Tables
Number of Products under Development by Stage of Development, H2 2017 10 Number of Products under Development by Therapy Areas, H2 2017 11 Number of Products under Development by Indications, H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15 Number of Products under Development by Companies, H2 2017 16 Products under Development by Companies, H2 2017 17 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 18 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 19 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 20 Number of Products under Investigation by Universities/Institutes, H2 2017 21 Products under Investigation by Universities/Institutes, H2 2017 22 Number of Products by Stage and Mechanism of Actions, H2 2017 23 Number of Products by Stage and Route of Administration, H2 2017 25 Number of Products by Stage and Molecule Type, H2 2017 27 Pipeline by AdAlta Ltd, H2 2017 28 Pipeline by Ambrx Inc, H2 2017 29 Pipeline by BioLineRx Ltd, H2 2017 29 Pipeline by Bristol-Myers Squibb Company, H2 2017 30 Pipeline by Eli Lilly and Company, H2 2017 31 Pipeline by Globavir Biosciences Inc, H2 2017 31 Pipeline by GlycoMimetics Inc, H2 2017 32 Pipeline by Pfizer Inc, H2 2017 33 Pipeline by Pharis Biotec GmbH, H2 2017 33 Pipeline by Polyphor Ltd, H2 2017 34 Pipeline by TaiGen Biotechnology Co Ltd, H2 2017 34 Pipeline by Upsher-Smith Laboratories Inc, H2 2017 35 Pipeline by X4 Pharmaceuticals Inc, H2 2017 35 Dormant Products, H2 2017 83 Dormant Products, H2 2017 (Contd..1), H2 2017 84 Dormant Products, H2 2017 (Contd..2), H2 2017 85 Dormant Products, H2 2017 (Contd..3), H2 2017 86 Discontinued Products, H2 2017 87
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
